{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:54:54Z","timestamp":1781628894074,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370232"],"award-info":[{"award-number":["82370232"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Arterial thrombotic diseases are leading causes of global morbidity and mortality, primarily driven by platelet hyperactivity. Qiliqiangxin capsules (QLQX), a traditional Chinese medicine approved in China for the treatment of heart failure, have exhibited potential benefits in reducing cardiovascular death. However, its direct effects on platelet activation and thrombosis remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Ex vivo platelet function assays demonstrated that oral QLQX inhibited agonist\u2011induced aggregation in platelet\u2011rich plasma (PRP) from chronic heart failure (CHF) patients and dose-dependently suppressed washed platelet aggregation in wild\u2011type mice. In parallel, QLQX administration attenuated platelet spreading and clot retraction in washed platelets from both patients with CHF and wild-type mice, and reduced ex vivo thrombus formation area in a microfluidic whole\u2011blood perfusion under arterial shear stress. Flow cytometry analysis revealed that QLQX did not affect the surface expression levels of the major platelet receptors, but reduced the activation of \u03b1IIb\u03b23 and P-selectin exposure induced by thrombin in mouse platelets. In vivo experiments demonstrated that QLQX treatment inhibited FeCl\u2083-induced thrombus formation in mesenteric arterioles, reduced collagen\/epinephrine-induced pulmonary embolism, and mitigated microvascular thrombosis during myocardial ischemia-reperfusion (I\/R) injury, without increasing bleeding in mice. RNA sequencing of platelets from QLQX- versus vehicle-treated mice identified differentially expressed genes enriched in the calcium signaling pathway, and functional assays demonstrated that QLQX inhibited agonist-induced platelet Ca\u00b2\u207a influx and PKC phosphorylation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>QLQX inhibits platelet activation and thrombosis by targeting Ca\u00b2\u207a influx and PKC signaling, supporting its potential therapeutic value in preventing thrombotic complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12959-025-00823-8","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T06:23:35Z","timestamp":1767421415000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Qiliqiangxin capsule attenuates platelet activation and thrombosis by suppressing Ca2+ influx and PKC signaling"],"prefix":"10.1186","volume":"24","author":[{"given":"Liping","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyu","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziru","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"823_CR1","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","volume":"118","author":"AM Wendelboe","year":"2016","unstructured":"Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ Res. 2016;118:1340\u20137. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306841.","journal-title":"Circ Res"},{"key":"823_CR2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41569-023-00854-6","volume":"20","author":"M Gawaz","year":"2023","unstructured":"Gawaz M, Geisler T, Borst O. Current concepts and novel targets for antiplatelet therapy. Nat Rev Cardiol. 2023;20:583\u201399. https:\/\/doi.org\/10.1038\/s41569-023-00854-6.","journal-title":"Nat Rev Cardiol"},{"key":"823_CR3","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ejvs.2009.01.009","volume":"37","author":"E Tournoij","year":"2009","unstructured":"Tournoij E, Peters RJ, Langenberg M, Kanhai KJ, Moll FL. The prevalence of intolerance for low-dose acetylsalicylacid in the secondary prevention of atherothrombosis. Eur J Vasc Endovasc Surg. 2009;37:597\u2013603. https:\/\/doi.org\/10.1016\/j.ejvs.2009.01.009.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"823_CR4","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/S0140-6736(20)30315-9","volume":"395","author":"M Chiarito","year":"2020","unstructured":"Chiarito M, Sanz-Sanchez J, Cannata F, Cao D, Sturla M, Panico C, Godino C, Regazzoli D, Reimers B, De Caterina R, et al. Monotherapy with a P2Y(12) inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet. 2020;395:1487\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(20)30315-9.","journal-title":"Lancet"},{"key":"823_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jacc.2021.10.027","volume":"79","author":"JA Bittl","year":"2022","unstructured":"Bittl JA, Laine L. Gastrointestinal injury caused by aspirin or clopidogrel monotherapy versus dual antiplatelet therapy. J Am Coll Cardiol. 2022;79:129\u201331. https:\/\/doi.org\/10.1016\/j.jacc.2021.10.027.","journal-title":"J Am Coll Cardiol"},{"key":"823_CR6","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.jacc.2013.05.035","volume":"62","author":"X Li","year":"2013","unstructured":"Li X, Zhang J, Huang J, Ma A, Yang J, Li W, Wu Z, Yao C, Zhang Y, Yao W, et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of Qili Qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol. 2013;62:1065\u201372. https:\/\/doi.org\/10.1016\/j.jacc.2013.05.035.","journal-title":"J Am Coll Cardiol"},{"key":"823_CR7","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1248\/bpb.b19-00050","volume":"42","author":"Q Zhao","year":"2019","unstructured":"Zhao Q, Li H, Chang L, Wei C, Yin Y, Bei H, Wang Z, Liang J, Wu Y. Qiliqiangxin attenuates oxidative Stress-Induced Mitochondrion-Dependent apoptosis in cardiomyocytes via PI3K\/AKT\/GSK3beta signaling pathway. Biol Pharm Bull. 2019;42:1310\u201321. https:\/\/doi.org\/10.1248\/bpb.b19-00050.","journal-title":"Biol Pharm Bull"},{"key":"823_CR8","doi-asserted-by":"publisher","first-page":"118821","DOI":"10.1016\/j.jep.2024.118821","volume":"337","author":"N Wu","year":"2025","unstructured":"Wu N, Chi J, Cai H, Hu J, Lai Y, Lin C, Kang L, Sun J, Huang J, Li M, et al. Traditional Chinese medication Qili Qiangxin capsule protects against myocardial ischemia-reperfusion injury through suppressing autophagy via the phosphoinositide 3-kinase\/protein kinase B\/forkhead box O3 axis. J Ethnopharmacol. 2025;337:118821. https:\/\/doi.org\/10.1016\/j.jep.2024.118821.","journal-title":"J Ethnopharmacol"},{"key":"823_CR9","first-page":"5655","volume":"12","author":"Y Lu","year":"2020","unstructured":"Lu Y, Wu J, Sun Y, Xin L, Jiang Z, Lin H, Zhao M, Cui X. Qiliqiangxin prevents right ventricular remodeling by inhibiting apoptosis and improving metabolism reprogramming with pulmonary arterial hypertension. Am J Transl Res. 2020;12:5655\u201369.","journal-title":"Am J Transl Res"},{"key":"823_CR10","doi-asserted-by":"publisher","first-page":"e0310897","DOI":"10.1371\/journal.pone.0310897","volume":"19","author":"M Sun","year":"2024","unstructured":"Sun M, Liu C, Gao K, Xu X, Chen K, Qiu L, Wang X. Qili Qiangxin capsule attenuates myocardial fibrosis by modulating collagen homeostasis post-infarction in rats. PLoS ONE. 2024;19:e0310897. https:\/\/doi.org\/10.1371\/journal.pone.0310897.","journal-title":"PLoS ONE"},{"key":"823_CR11","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1159\/000487871","volume":"45","author":"A Han","year":"2018","unstructured":"Han A, Lu Y, Zheng Q, Zhang J, Zhao Y, Zhao M, Cui X. Qiliqiangxin attenuates cardiac remodeling via Inhibition of TGF-beta1\/Smad3 and NF-kappaB signaling pathways in a rat model of myocardial infarction. Cell Physiol Biochem. 2018;45:1797\u2013806. https:\/\/doi.org\/10.1159\/000487871.","journal-title":"Cell Physiol Biochem"},{"key":"823_CR12","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-024-03169-2","volume":"30","author":"I Cheang","year":"2024","unstructured":"Cheang I, Yao W, Zhou Y, Zhu X, Ni G, Lu X, Liao S, Gao R, Zhou F, Shen J, et al. The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial. Nat Med. 2024;30:2295\u2013302. https:\/\/doi.org\/10.1038\/s41591-024-03169-2.","journal-title":"Nat Med"},{"key":"823_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/cvr\/cvae218","volume":"121","author":"W Zhang","year":"2025","unstructured":"Zhang W, Zhang Y, Han L, Bo T, Qi Z, Zhong H, Xu H, Hu L, Chen S, Zhang S. Double-stranded DNA enhances platelet activation, thrombosis, and myocardial injury via Cyclic GMP-AMP synthase. Cardiovasc Res. 2025;121:353\u201366. https:\/\/doi.org\/10.1093\/cvr\/cvae218.","journal-title":"Cardiovasc Res"},{"key":"823_CR14","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1093\/eurheartj\/ehac034","volume":"43","author":"Y Chen","year":"2022","unstructured":"Chen Y, Fu W, Zheng Y, Yang J, Liu Y, Qi Z, Wu M, Fan Z, Yin K, Chen Y, et al. Galectin 3 enhances platelet aggregation and thrombosis via Dectin-1 activation: a translational study. Eur Heart J. 2022;43:3556\u201374. https:\/\/doi.org\/10.1093\/eurheartj\/ehac034.","journal-title":"Eur Heart J"},{"key":"823_CR15","doi-asserted-by":"publisher","first-page":"151510","DOI":"10.1016\/j.bbrc.2025.151510","volume":"753","author":"H Zhong","year":"2025","unstructured":"Zhong H, Waresi M, Jia X, Ge J. Enhanced STIM1 expression drives platelet hyperactivity in diabetes. Biochem Biophys Res Commun. 2025;753:151510. https:\/\/doi.org\/10.1016\/j.bbrc.2025.151510.","journal-title":"Biochem Biophys Res Commun"},{"key":"823_CR16","doi-asserted-by":"publisher","first-page":"e041220","DOI":"10.1161\/JAHA.124.041220","volume":"14","author":"X Wu","year":"2025","unstructured":"Wu X, Pan G, Chang L, Liu Q, Liu Y, Zhang W, Guo Y, Zhang G, Zhong H, Qi Z, et al. Endoplasmic reticulum Stress-Induced triggering receptor expressed on myeloid cells 2 (TREM2) downregulation exacerbates platelet activation and myocardial infarction in patients with coronary artery disease. J Am Heart Assoc. 2025;14:e041220. https:\/\/doi.org\/10.1161\/JAHA.124.041220.","journal-title":"J Am Heart Assoc"},{"key":"823_CR17","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s44161-025-00637-x","volume":"4","author":"Z Qi","year":"2025","unstructured":"Qi Z, Zhang W, Zhang P, Qu Y, Zhong H, Zhou L, Zhou W, Yang W, Xu H, Zhao X, et al. The gut microbiota-bile acid-TGR5 axis orchestrates platelet activation and atherothrombosis. Nat Cardiovasc Res. 2025;4:584\u2013601. https:\/\/doi.org\/10.1038\/s44161-025-00637-x.","journal-title":"Nat Cardiovasc Res"},{"key":"823_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nature12613","volume":"503","author":"B Shen","year":"2013","unstructured":"Shen B, Zhao X, O\u2019Brien KA, Stojanovic-Terpo A, Delaney MK, Kim K, Cho J, Lam SC, Du X. A directional switch of integrin signalling and a new anti-thrombotic strategy. Nature. 2013;503:131\u20135. https:\/\/doi.org\/10.1038\/nature12613.","journal-title":"Nature"},{"key":"823_CR19","doi-asserted-by":"publisher","first-page":"378298","DOI":"10.1155\/2013\/378298","volume":"2013","author":"J Zhang","year":"2013","unstructured":"Zhang J, Wei C, Wang H, Tang S, Jia Z, Wang L, Xu D, Wu Y. Protective effect of Qiliqiangxin capsule on energy metabolism and myocardial mitochondria in pressure overload heart failure rats. Evid Based Complement Alternat Med. 2013;2013:378298. https:\/\/doi.org\/10.1155\/2013\/378298.","journal-title":"Evid Based Complement Alternat Med"},{"key":"823_CR20","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/s41467-020-14958-x","volume":"11","author":"D Kohler","year":"2020","unstructured":"Kohler D, Granja T, Volz J, Koeppen M, Langer HF, Hansmann G, Legchenko E, Geisler T, Bakchoul T, Eggstein C, et al. Red blood cell-derived semaphorin 7A promotes thrombo-inflammation in myocardial ischemia-reperfusion injury through platelet GPIb. Nat Commun. 2020;11:1315. https:\/\/doi.org\/10.1038\/s41467-020-14958-x.","journal-title":"Nat Commun"},{"key":"823_CR21","doi-asserted-by":"publisher","first-page":"122846","DOI":"10.1016\/j.lfs.2024.122846","volume":"351","author":"D Arauna","year":"2024","unstructured":"Arauna D, Araya-Maturana R, Urra FA, Garcia A, Palomo I, Fuentes E. Altered dynamics of calcium fluxes and mitochondrial metabolism in platelet activation-related disease and aging. Life Sci. 2024;351:122846. https:\/\/doi.org\/10.1016\/j.lfs.2024.122846.","journal-title":"Life Sci"},{"key":"823_CR22","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1093\/eurheartj\/ehl305","volume":"27","author":"I Chung","year":"2006","unstructured":"Chung I, Lip GY. Platelets and heart failure. Eur Heart J. 2006;27:2623\u201331. https:\/\/doi.org\/10.1093\/eurheartj\/ehl305.","journal-title":"Eur Heart J"},{"key":"823_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2013.07.007","volume":"2","author":"PA Gurbel","year":"2014","unstructured":"Gurbel PA, Tantry US. Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives. JACC Heart Fail. 2014;2:1\u201314. https:\/\/doi.org\/10.1016\/j.jchf.2013.07.007.","journal-title":"JACC Heart Fail"},{"key":"823_CR24","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/ehf2.15090","volume":"12","author":"G D\u2019Italia","year":"2025","unstructured":"D\u2019Italia G, Schroen B, Cosemans J. Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities. ESC Heart Fail. 2025;12:1013\u201328. https:\/\/doi.org\/10.1002\/ehf2.15090.","journal-title":"ESC Heart Fail"},{"key":"823_CR25","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2337\/dc08-2064","volume":"32","author":"DJ Angiolillo","year":"2009","unstructured":"Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care. 2009;32:531\u201340. https:\/\/doi.org\/10.2337\/dc08-2064.","journal-title":"Diabetes Care"},{"key":"823_CR26","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.phymed.2018.03.003","volume":"44","author":"F Zhang","year":"2018","unstructured":"Zhang F, Zhang Y, Li X, Zhang S, Zhu M, Du W, Xiao X. Research on Q-markers of Qiliqiangxin capsule for chronic heart failure treatment based on pharmacokinetics and pharmacodynamics association. Phytomedicine. 2018;44:220\u201330. https:\/\/doi.org\/10.1016\/j.phymed.2018.03.003.","journal-title":"Phytomedicine"},{"key":"823_CR27","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1002\/jssc.202101008","volume":"45","author":"XY Tang","year":"2022","unstructured":"Tang XY, Dai ZQ, Zeng JX, Li ZT, Fan CL, Yao ZH, Yao XS, Dai Y. Pharmacokinetics, hepatic disposition, and heart tissue distribution of 14 compounds in rat after oral administration of Qi-Li-Qiang-Xin capsule via ultra-high-performance liquid chromatography coupled with triple quadrupole tandem mass spectrometry. J Sep Sci. 2022;45:2177\u201389. https:\/\/doi.org\/10.1002\/jssc.202101008.","journal-title":"J Sep Sci"},{"key":"823_CR28","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1111\/bph.17434","volume":"182","author":"Y Wang","year":"2025","unstructured":"Wang Y, Liu L, Li J, You Y, Xiao S, Feng J, Yin X, Liao F, You Y. Involvement of piezo 1 in Inhibition of shear-induced platelet activation and arterial thrombosis by ginsenoside Rb1. Br J Pharmacol. 2025;182:1957\u201374. https:\/\/doi.org\/10.1111\/bph.17434.","journal-title":"Br J Pharmacol"},{"key":"823_CR29","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jgr.2025.04.002","volume":"49","author":"AW Akram","year":"2025","unstructured":"Akram AW, Shin JH, Batmunkh U, Saba E, Kang YM, Jung S, Han JE, Kim SD, Kwak D, Kwon HW, et al. Ginsenoside Rg5 inhibits platelet aggregation by regulating GPVI signaling pathways and ferric chloride-induced thrombosis. J Ginseng Res. 2025;49:460\u20139. https:\/\/doi.org\/10.1016\/j.jgr.2025.04.002.","journal-title":"J Ginseng Res"},{"key":"823_CR30","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1186\/s13018-023-03948-6","volume":"18","author":"W Fan","year":"2023","unstructured":"Fan W, Lan S, Yang Y, Liang J. Network Pharmacology prediction and molecular docking-based strategy to discover the potential Pharmacological mechanism of Huang-Qi-Gui-Zhi-Wu-Wu Decoction against deep vein thrombosis. J Orthop Surg Res. 2023;18:475. https:\/\/doi.org\/10.1186\/s13018-023-03948-6.","journal-title":"J Orthop Surg Res"},{"key":"823_CR31","doi-asserted-by":"publisher","first-page":"118622","DOI":"10.1016\/j.jep.2024.118622","volume":"335","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zhang JX, Xiao LX, Zheng JT, Qu XT, Liu Y, Meng J, Liu CS. The synergistic effect of Huangqi gegen Decoction on thrombosis relates to the astragalus polysaccharide-improved oral delivery of puerarin. J Ethnopharmacol. 2024;335:118622. https:\/\/doi.org\/10.1016\/j.jep.2024.118622.","journal-title":"J Ethnopharmacol"},{"key":"823_CR32","doi-asserted-by":"publisher","first-page":"4707","DOI":"10.2147\/JIR.S312167","volume":"14","author":"C Pei","year":"2021","unstructured":"Pei C, Wang F, Huang D, Shi S, Wang X, Wang Y, Li S, Wu Y, Wang Z. Astragaloside IV protects from PM2.5-Induced lung injury by regulating autophagy via Inhibition of PI3K\/Akt\/mTOR signaling in vivo and in vitro. J Inflamm Res. 2021;14:4707\u201321. https:\/\/doi.org\/10.2147\/JIR.S312167.","journal-title":"J Inflamm Res"},{"key":"823_CR33","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1007\/s11033-021-06204-4","volume":"48","author":"Y Zang","year":"2021","unstructured":"Zang Y, Liu S, Cao A, Shan X, Deng W, Li Z, Wang H, Wang Y, Wang L, Peng W. Astragaloside IV inhibits palmitic acid-induced apoptosis through regulation of calcium homeostasis in mice podocytes. Mol Biol Rep. 2021;48:1453\u201364. https:\/\/doi.org\/10.1007\/s11033-021-06204-4.","journal-title":"Mol Biol Rep"},{"key":"823_CR34","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.thromres.2008.05.020","volume":"123","author":"YP Wu","year":"2008","unstructured":"Wu YP, Zhao XM, Pan SD, Guo DA, Wei R, Han JJ, Kainoh M, Xia ZL, de Groot PG, Lisman T. Salvianolic acid B inhibits platelet adhesion under conditions of flow by a mechanism involving the collagen receptor alpha2beta1. Thromb Res. 2008;123:298\u2013305. https:\/\/doi.org\/10.1016\/j.thromres.2008.05.020.","journal-title":"Thromb Res"},{"key":"823_CR35","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1111\/jcmm.13572","volume":"22","author":"Y Wang","year":"2018","unstructured":"Wang Y, Han X, Fu M, Wang J, Song Y, Liu Y, Zhang J, Zhou J, Ge J. Qiliqiangxin attenuates hypoxia-induced injury in primary rat cardiac microvascular endothelial cells via promoting HIF-1alpha-dependent Glycolysis. J Cell Mol Med. 2018;22:2791\u2013803. https:\/\/doi.org\/10.1111\/jcmm.13572.","journal-title":"J Cell Mol Med"},{"key":"823_CR36","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.2174\/1381612826666201005152709","volume":"27","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhang J, Fu M, Wang J, Cui X, Song Y, Han X, Liu Y, Zhou J, Ge J. Qiliqiangxin prescription promotes angiogenesis of hypoxic primary rat cardiac microvascular endothelial cells via regulating miR-21 signaling. Curr Pharm Des. 2021;27:2966\u201374. https:\/\/doi.org\/10.2174\/1381612826666201005152709.","journal-title":"Curr Pharm Des"},{"key":"823_CR37","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1002\/ejhf.3068","volume":"25","author":"M Packer","year":"2023","unstructured":"Packer M, Qiliqiangxin. A multifaceted holistic treatment for heart failure or a Pharmacological probe for the identification of cardioprotective mechanisms? Eur J Heart Fail. 2023;25:2130\u201343. https:\/\/doi.org\/10.1002\/ejhf.3068.","journal-title":"Eur J Heart Fail"},{"key":"823_CR38","doi-asserted-by":"publisher","first-page":"9926635","DOI":"10.1155\/2022\/9926635","volume":"2022","author":"Y Qin","year":"2022","unstructured":"Qin Y, Lv C, Zhang X, Ruan W, Xu X, Chen C, Wan X, Ji X, Zhou J, Lu L, et al. Protective effect of Qiliqiangxin against Doxorubicin-Induced cardiomyopathy by suppressing excessive autophagy and apoptosis. Cardiovasc Ther. 2022;2022:9926635. https:\/\/doi.org\/10.1155\/2022\/9926635.","journal-title":"Cardiovasc Ther"},{"key":"823_CR39","doi-asserted-by":"publisher","first-page":"9361077","DOI":"10.1155\/2022\/9361077","volume":"2022","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang Z, Hao X, Yu T, Li S. Qiliqiangxin capsule modulates calcium transients and calcium sparks in human induced pluripotent stem Cell-Derived cardiomyocytes. Evid Based Complement Alternat Med. 2022;2022:9361077. https:\/\/doi.org\/10.1155\/2022\/9361077.","journal-title":"Evid Based Complement Alternat Med"},{"key":"823_CR40","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/clc.4960120811","volume":"12","author":"N Kobayashi","year":"1989","unstructured":"Kobayashi N, Okumura K, Hashimoto H, Ito T, Satake T. Increased Ca2\u2009+\u2009influx into platelets induced by thromboxane A2 analog in patients with ischemic heart disease. Clin Cardiol. 1989;12:456\u201360. https:\/\/doi.org\/10.1002\/clc.4960120811.","journal-title":"Clin Cardiol"},{"key":"823_CR41","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1538-7836.2011.04550.x","volume":"10","author":"Z Zhu","year":"2012","unstructured":"Zhu Z, Zhou H, Yu X, Chen L, Zhang H, Ren S, Wu Y, Luo D. Potential regulatory role of calsequestrin in platelet Ca(2+) homeostasis and its association with platelet hyperactivity in diabetes mellitus. J Thromb Haemost. 2012;10:116\u201324. https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04550.x.","journal-title":"J Thromb Haemost"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-025-00823-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-025-00823-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-025-00823-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:01:41Z","timestamp":1781625701000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12959-025-00823-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["823"],"URL":"https:\/\/doi.org\/10.1186\/s12959-025-00823-8","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"19 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments using human subjects were performed in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Huashan Hospital, Fudan University. Written informed consent was obtained from participants. All animal procedures were approved by the Animal Care Ethics Committee of Fudan University and followed the Guidelines for the Care and Use of Laboratory Animals (National Research Council, 8th edition, 2011).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consented to the publication of the findings.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}